LATEST NEWS 2020年3月20日

Researchers at the University of Tokyo Identified An Existing Drug That Can Prevent Novel Coronavirus Infection

    Researchers at the University of Tokyo (UTokyo) announced on March 18 that they identified a drug that could prevent novel coronavirus infections by stopping virus entry into human cells at the early stage of infection. 

 

    Professor Junichiro Inoue and Assistant Professor Mizuki Yamamoto at the Institute of Medical Science, The University of Tokyo, said that they found Nafamostat to be effective in inhibiting novel coronavirus infection.

 

    Nafamostat is a substance used as a treatment for acute pancreatitis. A Japanese medical company, Nichi-Iko, developed the drug and sells it under the brand name “Fusan”. The patent of the drug has expired and cheaper generic drugs already appear on the market.

 

Professor Inoue giving a presentation at the press conference (Photo by Yoshiki Nakano)

 

    According to Professor Inoue, Nafamostat possibly prevents the first stage of infection, which is the fusion of the outer membrane of the SARS-CoV-2 with the human cell membrane. SARS-CoV-2 is the causative agent of the novel coronavirus infection (COVID-19).

 

    The effort to find an effective medication for COVID-19 is in progress in Japan and other countries. German researchers announced in early March that they found Camostat, a drug similar to Nafamostat, to be effective. 

 

    Camostat was also developed in Japan and has been prescribed as a treatment for acute pancreatitis and other diseases under the brand name “Foipan.” However, according to the German researchers, patients need to be given higher doses of Camostat than the common use of the medicine in order to prevent the novel coronavirus infection. Another problem is that Camostat is approved only in Japan and Korea, so it will take time to use it as a treatment on humans in most countries.

 

    According to the announcement of UTokyo, Nafamostat can prevent the process of coronavirus infection with less than one-tenth concentration of Casmostat. Nafamostat is widely used in Japan and proves to be safe based on a sufficient number of clinical data. Thus, researchers can smoothly move on to clinical trials with Nafamostat, Professor Inoue said.

 

Interviewees wore masks and the front seats were required to be empty. (Photo by Yoshiki Nakano)

 

    ”Professor Inoue and his team’s discovery is not published as a scholarly work yet,” President Makoto Gonokami of UTokyo said, “but I decided to hold a press conference considering its significant impact on society.” He also announced the university’s commitment to contain the novel coronavirus. 

 

    Professor Kyoji Moriya at the Department of Infection Control and Prevention, The University of Tokyo Hospital, explained that the researchers planned to work on the clinical applications of the new findings from this month to the beginning of next month, cooperating with hospitals and research institutes such as the National Center for Global Health and Medicine.

 

*This is an English version of the news flash published on March 18th

 

同じ記者の記事

関連記事

合わせて読みたい

COLUMN 2020年03月26日

【東大新聞オンラインPICK UP】〜健康・医療編〜 健康や医療を多角的に考える

NEWS 2020年02月06日

生体認証と健康状態 新開発のシート型イメージセンサーで同時計測が可能に

COLUMN 2019年09月30日

Take a Walk through Todai’s Campuses with Dr. Thurgill #4 General Library, Hongo Campus 【Part 1】

NEWS 2020年03月19日

教養・総合文化、オンライン授業の大規模な導入へ 新入生に事前準備を要請

NEWS 2020年02月21日

東大、合格者受験番号の掲示を中止 新型コロナウイルスの感染拡大防止のため

TOPに戻る